

Supplementary Material

Synthesis of New *N*-Norbonylimide Substituted Amide Derivatives: Their Reductive Heck and Domino Heck Reactions

Fatma Albayrak^a, Omer Tahir Gunkara^{b*}, Elif Basak Ersoy^b, Nuket Ocal^{b*} and Dieter E. Kaufmann^c

^aDepartment of Chemistry, Faculty of Science, Gebze Technical University, TR 41400, Gebze, Kocaeli, Turkey

^bChemistry Department, Faculty of Science and Arts, Yildiz Technical University, Davutpasa Campus, Istanbul, Turkey

^cInstitute of Organic Chemistry, Clausthal University of Technology, Leibnizstr. 6, 38678 Clausthal-Zellerfeld, Germany


Email: gunkara@yildiz.edu.tr, nocal@yildiz.edu.tr

Table of Contents

- | | |
|--|----|
| 1. List of the all synthesized compound structure (Table S1) | S2 |
| 2. FTIR, ¹ H NMR, ¹³ C NMR, HRMS (or GC-MS) spectra of all compounds | S4 |

Table S1. List of the synthesized compound structure.

Entry	Compound Name	Compound Structure
4	2-(4-Azabicyclo[2.2.1]hept-8-ene-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl)-3-methyl pentanoyl chloride	
5	<i>N</i> -4-Azabicyclo[2.2.1]hept-8-ene-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl 2-(4-azabicyclo[2.2.1]hept-8-ene-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl)-3-methylpentanamide	
6a	<i>N</i> -[8-Phenyl-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl] 2-(8-phenyl-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl)-3-methylpentanamide	
6b	<i>N</i> -[8-(4-chlorophenyl)-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl]-2-(8-(4-chlorophenyl)-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl)-3-methylpentanamide	
6c	<i>N</i> -[8-Morpholino-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl] 2-(8-morpholino-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl)-3-methylpentanamide	
6d	<i>N</i> -[8-(2-thienyl)-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl] 2-(8-(2-thienyl)-4-azabicyclo[2.2.1]heptane-3- <i>endo</i> ,5- <i>endo</i> -dicarboximide-4-yl)-3-methylpentanamide	






Figure S1. FTIR Spectrum of Compound 4 (ATR).




Figure S2. ^1H NMR Spectrum of Compound 4 (CDCl_3).




Figure S3. APT Spectrum of Compound 4 (CDCl₃).




Figure S4. GC-MS Spectrum of Compound 4.




Figure S5. FTIR Spectrum of Compound 5 (ATR).




Figure S6. ^1H NMR Spectrum of Compound 5 (CDCl_3).




Figure S7. APT Spectrum of Compound 5 (CDCl₃).




Figure S8. QToF Spectrum of Compound 5.





Figure S9. FTIR Spectrum of Compound 6a (ATR).

Figure S10. ^1H NMR Spectrum of Compound 6a (CDCl_3).




Figure S11. APT Spectrum of Compound 6a (CDCl₃).






Figure S12. QToF Spectrum of Compound 6a.

Figure S13. FTIR Spectrum of Compound **6b** (ATR).Figure S14. ^1H NMR Spectrum of Compound **6b** (CDCl_3).




Figure S15. APT Spectrum of Compound **6b** (CDCl_3).






Figure S16. QToF Spectrum of Compound **6b**.

Figure S17. FTIR Spectrum of Compound **6c** (ATR).Figure S18. ¹H NMR Spectrum of Compound **6c** (CDCl₃).




Figure S19. APT Spectrum of Compound **6c** (CDCl_3).




Figure S20. QToF Spectrum of Compound **6c**.





Figure S21. FTIR Spectrum of Compound 6d (ATR).

Figure S22. ^1H NMR Spectrum of Compound 6d (CDCl_3).



Figure S23. APT Spectrum of Compound 6d (CDCl₃).

Figure S24. QToF Spectrum of Compound 6d.





Figure S25. FTIR Spectrum of Compound 6e (ATR).

Figure S26. ¹H NMR Spectrum of Compound 6e (CDCl₃).




Figure S27. APT Spectrum of Compound **6e** (CDCl_3).




Figure S28. QToF Spectrum of Compound **6e**.





Figure S29. FTIR Spectrum of Compound 7a (ATR).

Figure S30. ¹H NMR Spectrum of Compound 7a (CDCl₃).




Figure S31. APT Spectrum of Compound 7a (CDCl₃).




Figure S32. QToF Spectrum of Compound 7a.





Figure S33. FTIR Spectrum of Compound 8 (ATR).

Figure S34. ¹H NMR Spectrum of Compound 8 (CDCl₃).




Figure S35. APT Spectrum of Compound 8 (CDCl₃).




Figure S36. GC-MS Spectrum of Compound 8.





Figure S37. FTIR Spectrum of Compound 9a (ATR).

Figure S38. ¹H NMR Spectrum of Compound 9a (CDCl₃).



Figure S39. APT Spectrum of Compound 9a (CDCl₃).

Figure S40. QToF Spectrum of Compound 9a.







Figure S41. FTIR Spectrum of Compound 9b (ATR).

Figure S42. ¹H NMR Spectrum of Compound 9b (CDCl₃).

Figure S43. APT Spectrum of Compound **9b** (CDCl_3).Figure S44. QToF Spectrum of Compound **9b**.